The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

One major reason why it has been difficult to develop an effective HIV vaccine is that the virus mutates very rapidly, allowing it to evade the antibody response generated by vaccines. Several ...

The simple quantitation of HIV-specific antibody by ELISA or Western Blot after vaccination is not sufficient owing to the vast majority of this antibody being nonprotective. Thus assays must ...

Researchers have shown that they can generate a strong immune response against HIV with two doses of a vaccine given one week apart. One major reason why it has been difficult to develop an ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Neutralizing antibodies Each year, HIV infects more than 1 million people around the world, and some of those people do not have access to antiviral drugs. An effective vaccine could prevent many ...

The purpose of vaccinating children was originally to stop dangerous diseases that spread easily and quickly in a school room ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for ...

Failure to ensure that everyone has access to prevention options to protect oneself from HIV acquisition, has resulted in at ...

Eddy Micah Jr./ Isaac Mugabi/ Isaac Kaledzi 10/15/2024 October 15, 2024 Significant progress has been made in producing drugs that can help the 26 million people across Africa living with HIV. But ...

Press Release - New data from the PURPOSE 2 study of twice-yearly lenacapavir for HIV prevention are among the scientific highlights at HIVR4P 2024, the 5th HIV Research for Prevention Conference, ...

The Institute of Human Virology, Nigeria, has announced plans to establish a learning and development centre to offer ...